Company Overview

**OncoSec Medical Incorporated** is a biopharmaceutical company developing its investigational immunotherapy, TAVO, for the treatment of cancer. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of TAVO have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating TAVO for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate TAVO in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

**OncoSec To Present At BIO CEO & Investor Conference**
Feb 8 2019, 8:00 AM EST

**OncoSec Provides KEYNOTE-695 Clinical Update And Outlines 2019 Milestones**
Feb 1 2019, 8:00 AM EST

**OncoSec to Host 2019 Business Outlook Conference Call on February 1, 2019**
Jan 22 2019, 8:00 AM EST

**Stock Overview**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>ONCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>Nasdaq</td>
</tr>
<tr>
<td>Market Cap</td>
<td>36.18m</td>
</tr>
<tr>
<td>Last Price</td>
<td>$0.5608</td>
</tr>
<tr>
<td>52-Week</td>
<td>$0.541 - $2.21</td>
</tr>
</tbody>
</table>

**Investor Relations**

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

02/25/2019 04:00 PM EST

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.